2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
20
Active not recruiting
14
Recruiting
9
Terminated
8
Withdrawn
4
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
1
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cisplatin
517
Radiotherapy
378
Cyclophosphamide
368
Carboplatin
359
Capecitabine
342
Paclitaxel
337
Oxaliplatin
336
Gemcitabine
322
Docetaxel
317
Fluorouracil
291
Drug Therapy
277
Bevacizumab
249
apatinib
247
camrelizumab
219
Etoposide
201
Irinotecan
183
Doxorubicin
181
Leucovorin
164
Dexamethasone
161
pembrolizumab
155
Neoadjuvant Therapy
146
sintilimab
145
anlotinib
140
Blood Specimen Collection
140
Pemetrexed
138
Cytarabine
138
toripalimab
133
Surgical Procedures, Operative
131
Radiosurgery
131
S 1 (combination)
125
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Tiragolumab
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled
NCT05034055
2021-09-05
SKYROCKET
Yonsei University
Phase 2
Unknown
45 enrolled